Scholarlink

<p>Data on the efficacy of computer tomography guided brachytherapy (CT-BRT) for limited liver metastases is lacking; to assess CT-BRT’s role in inducedoligoprogression in colorectal cancer (CRC), we performed a retrospective cohort study on CRC patients with metastatic disease, treated with 2–5 lines of systemic therapy, who achieved induced oligoprogression with up to four liver metastases eligible for CTBRT. In 75 patients, median overall survival (mOS) was 17&#xa0;months, and median progression-free survival (mPFS) was 10&#xa0;months during a 16-month follow-up. The mOS was not dose-dependent. Complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) were found in 8, 31, 47, and 15%, respectively. The mOS in patients with CR, PR, SD, and PD was 23, 17, 14, and 11&#xa0;months, respectively. Disease Control Rate (DCR) with a high dose influenced OS, while PFS was impacted by extrahepatic metastases (especially in abdominal/pelvic lymph nodes), the number of metastases, and DCR with a high dose. Treatment toxicity was very low (Grade 3—1%, &gt; Grade 3–0%). We report the largest cohort demonstrating CT-BRT as an effective local treatment for colorectal liver metastases in induced oligoprogression, with minimal toxicity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Computed tomography guided high dose rate brachytherapy for induced oligoprogression of colorectal cancer liver metastases

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月2日

查看全文
  • Paweł Cisek,
  • Łukasz Kuncman,
  • Barbara Alicja Jereczek-Fossa,
  • Ewa Wojtyna,
  • Magdalena Orzechowska,
  • Sylwia Sroka,
  • Izabela Kordzińska-Cisek,
  • Jacek Fijuth,
  • Mateusz Bilski

摘要

Data on the efficacy of computer tomography guided brachytherapy (CT-BRT) for limited liver metastases is lacking; to assess CT-BRT’s role in inducedoligoprogression in colorectal cancer (CRC), we performed a retrospective cohort study on CRC patients with metastatic disease, treated with 2–5 lines of systemic therapy, who achieved induced oligoprogression with up to four liver metastases eligible for CTBRT. In 75 patients, median overall survival (mOS) was 17 months, and median progression-free survival (mPFS) was 10 months during a 16-month follow-up. The mOS was not dose-dependent. Complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) were found in 8, 31, 47, and 15%, respectively. The mOS in patients with CR, PR, SD, and PD was 23, 17, 14, and 11 months, respectively. Disease Control Rate (DCR) with a high dose influenced OS, while PFS was impacted by extrahepatic metastases (especially in abdominal/pelvic lymph nodes), the number of metastases, and DCR with a high dose. Treatment toxicity was very low (Grade 3—1%, > Grade 3–0%). We report the largest cohort demonstrating CT-BRT as an effective local treatment for colorectal liver metastases in induced oligoprogression, with minimal toxicity.